Tonix Pharmaceuticals Announces Accelerating Completion Of Enrollment In Phase 2 Uplift Study Of TNX-601 ER For Major Depressive Disorder; Topline Data Now Expected In Q4 2023
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals has announced that it is accelerating the completion of enrollment in its Phase 2 Uplift study of TNX-601 ER for Major Depressive Disorder. The company now expects topline data to be available in Q4 2023.
July 26, 2023 | 8:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tonix Pharmaceuticals' decision to accelerate the completion of enrollment in its Phase 2 Uplift study could potentially expedite the drug's approval process, which may positively impact the company's stock in the short term.
The acceleration of the Phase 2 Uplift study enrollment suggests that Tonix Pharmaceuticals is making significant progress in its drug development process. This could potentially expedite the drug's approval process, which would likely be viewed positively by investors and could lead to an increase in the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100